Understanding Virologic Responses in Chronic Hepatitis B Treatment
NIHR Oxford Biomedical Research Centre, Oxford, UK
2024
n=1885
publication
10 minutes
Evidence: high
Wang Tingyan, Campbell Cori, Stockdale Alexander J., Todd Stacy, McIntyre Karl, Frankland Andrew, Jaworski Jakub, Glampson Ben, Papadimitriou Dimitri, Mercuri Luca, Mayer Erik, Jones Christopher R., Salih Hizni, Roadknight Gail, Little Stephanie, Noble Theresa, Várnai Kinga A., Davis Cai, Heinson Ashley I., George Michael, Borca Florina, English Louise, Romão Luis, Ramlakhan David, Barnes Eleanor, Matthews Philippa C., Gelson William, Cooke Graham S., Khakoo Salim I., Nastouli Eleni, Davies Jim, Woods Kerrie, Ryder Stephen, Elsharkawy Ahmed, Easom Nicholas, Bernal William, Ahmad Shazaad, Macdonald Douglas, MacNaughton Heidi, Kim Yun, Meneses Josune Olza, Roberts Timothy, Roberts Lara, Higgins Finola, Vilar Javier, Norris Ruth, Tilston George, Serafimova Ilina, Montague Sarah, Verheyden Juliette, Juurlink Irene, Jack Kathryn, Waldren-Glenn Alex, Poole Lizzie, Day Victoria, Reglar Berit
Title
Understanding Virologic Responses in Chronic Hepatitis B Treatment
Hypothesis
What are the distinct virologic trajectories in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy?
Conclusion
There is significant heterogeneity in virologic response to nucleos(t)ide analogue therapy in chronic hepatitis B patients, with over 20% showing potentially suboptimal responses.